TGA: Medicinal cannabis quality rules updated
The Australian regulatory authority for therapeutic goods TGA has updated its 19-pages quality requirements for medical cannabis products. These are now in line with TGO 93 and refer to
- any medicinal cannabis product imported into or supplied in Australia
- cannabis plant used in the manufacture of medicinal cannabis products e.g., as an ingredient or as a starting material for an extract used as an ingredient
- any other ingredients used in the manufacture of medicinal cannabis products, such as excipients
- steps and procedures carried out in the manufacture of medicinal cannabis product.
According to the revised TGO 93 version of March 2022, imports of medicinal cannabis must meet GMP requirements, date child-resistant closures on high-risk goods and fulfil the requirements for microbiological testing. These requirements come along with a transition period until 1 July 2023 for compliance. All medicinal cannabis products released from that date need to comply with the requirements of TGO 93.
It is specified for the UK, Canada, South Africa and Israel, which GMP standards need to be followed and which evidence has to be kept. Any products manufactured in other countries than those, an application has to be made to the TGA requesting an inspection of the manufacturing facility. The TGA will inspect for compliance according to the PIC/S Code of GMP, as adopted by Australia, and provide written confirmation of the results of the inspection.
Source:
Guidance on quality requirements for medicinal cannabis products
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
